TY - JOUR
T1 - The Distinctive Clinical Features of Paraneoplastic Sensory Neuronopathy
AU - Chalk, Colin H.
AU - Windebank, Anthony J.
AU - Kimmel, David W.
AU - Mcmanis, Philip G.
PY - 1992/8
Y1 - 1992/8
N2 - A 15-year experience with paraneoplastic sensory neuronopathy at the Mayo Clinic is reviewed. Of 26 patients with paraneoplastic sensory neuronopathy, 19 had small cell lung cancer, 4 had breast cancer, and 3 had other neoplasms. There was a striking predominance of females (20:6). Neuropathic symptoms (pain, paresthesia, sensory loss) were asymmetric at onset, with a predilection for the upper limbs; in three patients, symptoms were confined to the arms. Electrophysiologic testing revealed absent sensory responses and normal or minimally altered motor responses. Slightly more than half the patients had associated autonomic, cerebellar, or cerebral abnormalities. In some patients, treatment of the neoplasm seemed to halt progression of the neuronopathy, but none had neurologic improvement and most continued to worsen, even when the oncologic response was good. Distinguishing between paraneoplastic and nonparaneoplastic sensory neuronopathies can be difficult, but prominent neuropathic pain, neurologic dysfunction involving more than the peripheral sensory system, or an increased cerebrospinal fluid protein value should prompt a careful search for a cancer.
AB - A 15-year experience with paraneoplastic sensory neuronopathy at the Mayo Clinic is reviewed. Of 26 patients with paraneoplastic sensory neuronopathy, 19 had small cell lung cancer, 4 had breast cancer, and 3 had other neoplasms. There was a striking predominance of females (20:6). Neuropathic symptoms (pain, paresthesia, sensory loss) were asymmetric at onset, with a predilection for the upper limbs; in three patients, symptoms were confined to the arms. Electrophysiologic testing revealed absent sensory responses and normal or minimally altered motor responses. Slightly more than half the patients had associated autonomic, cerebellar, or cerebral abnormalities. In some patients, treatment of the neoplasm seemed to halt progression of the neuronopathy, but none had neurologic improvement and most continued to worsen, even when the oncologic response was good. Distinguishing between paraneoplastic and nonparaneoplastic sensory neuronopathies can be difficult, but prominent neuropathic pain, neurologic dysfunction involving more than the peripheral sensory system, or an increased cerebrospinal fluid protein value should prompt a careful search for a cancer.
UR - http://www.scopus.com/inward/record.url?scp=0026655735&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026655735&partnerID=8YFLogxK
U2 - 10.1017/S0317167100041974
DO - 10.1017/S0317167100041974
M3 - Article
C2 - 1393844
AN - SCOPUS:0026655735
SN - 0317-1671
VL - 19
SP - 346
EP - 351
JO - Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
JF - Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
IS - 3
ER -